Showing results (511-520 of 536) with videos related to

Sort By:
Pageof 54
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
The Journal of Urology|August 1, 1995
Complications of laparoscopic nephrectomy in 185 patients: a multi-institutional reviewI S Gill, L R Kavoussi, R V Clayman, et al.
Cancer Research|August 25, 2011
p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behaviorDevin T Rosenthal, Harish Iyer, Silvia Escudero, et al.
American Journal of Hypertension|September 12, 2000
Factors affecting blood pressure responses to diet: the Vanguard studyL M Resnick, S Oparil, A Chait, et al.
The American Journal of Clinical Nutrition|December 1, 1996
Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared dietD C Hatton, R B Haynes, S Oparil, et al.
American Journal of Surgery|May 1, 1996
The role of whole organ pancreas transplantation in the treatment of type I diabetesM Kinkhabwala, A Wilkinson, G Danovitch, et al.
Transplantation Proceedings|December 1, 1986
Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatographyG J Burckart, R Venkataramanan, R J Ptachcinski, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Lancet (London, England)|March 17, 1984
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapyT E Starzl, M A Nalesnik, K A Porter, et al.
Pageof 54